Literature DB >> 9464511

Homozygous deletions of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma.

Z Piao1, C Park, J S Lee, C H Yang, K Y Choi, H Kim.   

Abstract

To elucidate the alterations of CDKN2 in hepatocarcinogenesis, we performed a loss of heterozygosity (LOH) study using eight polymorphic markers surrounding the CDKN2 gene and analyzed the homozygous deletions and mutations of the CDKN2 gene in 41 primary hepatocellular carcinomas (HCCs). Frequent LOH (27.8-44%) was found in the eight loci on chromosome 9p, however, no intragenic mutations of CDKN2 were observed by PCR-SSCP analysis. Homozygous deletions were detected in 25 of 41 HCCs (61%) by a comparative multiplex PCR. No expression of the CDKN2 protein was noted in five out of nine available HCCs by Western blot analysis. These results suggest that inactivation of the CDKN2 gene in HCC is a frequent event in which homozygous deletions are the most common mechanism of CDKN2 inactivation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9464511     DOI: 10.1016/s0304-3835(97)00403-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA.

Authors:  Jie Ding; Shenglin Huang; Shunquan Wu; Yingjun Zhao; Linhui Liang; Mingxia Yan; Chao Ge; Jian Yao; Taoyang Chen; Dafang Wan; Hongyang Wang; Jianren Gu; Ming Yao; Jinjun Li; Hong Tu; Xianghuo He
Journal:  Nat Cell Biol       Date:  2010-03-21       Impact factor: 28.824

2.  Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus.

Authors:  H Kaneto; S Sasaki; H Yamamoto; F Itoh; M Toyota; H Suzuki; I Ozeki; N Iwata; T Ohmura; T Satoh; Y Karino; T Satoh; J Toyota; M Satoh; T Endo; M Omata; K Imai
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

Review 3.  Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 4.  Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda; Toshifumi Wakai; Masayuki Kubota; Masaaki Takamura; Satoshi Yamagiwa; Yutaka Aoyagi; Mami Osawa; Shun Fujimaki; Ayumi Sanpei; Takuya Genda; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2013-05-03       Impact factor: 2.309

Review 5.  Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know.

Authors:  Jacek Baj; Łukasz Bryliński; Filip Woliński; Michał Granat; Katarzyna Kostelecka; Piotr Duda; Jolanta Flieger; Grzegorz Teresiński; Grzegorz Buszewicz; Marzena Furtak-Niczyporuk; Piero Portincasa
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.